Evidence map›Paper›PMID 34814389›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: a 2021 update].

Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. [Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  3. [New progress in the first-line treatment of advanced hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  4. Article
  5. [The consensus on tertiary prevention of primary liver cancer (2022 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of anti-HBV and HCV therapy, experts in related fields organized by the Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association updated "Experts Consensus on Antiviral Therapy for HBV/ HCV-related Hepatocellular Carcinoma" . On the basis of previous expert recommendations/consensus and the new evidence in recent years, this new consensus was developed, and the relevant recommendations are provided to hepatologists, epidemiologists, medical doctors and specialists working in community service centers and primary health care institutions for guidance of hepatocellular carcinoma antiviral treatment.

Indexed as

Carcinoma, HepatocellularHepatitis CLiver NeoplasmsAntiviral AgentsHepatitis B virusHumansAntiviral AgentsConsensusHepaocellular carcinomaHepatitis B virusHepatitis C virusTherapeutics

Identifiers

PMID34814389
PMCPMC12814204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.